WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that various members of its management and advisory team will be presenting at the 2nd Annual Oligonucleotides-based Therapeutics Conference, being held September 22 to 24, 2008 at the Fairview Park Marriott in Falls Church, Virginia. Presentations are as follows:
